eccogene glp-1 Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China Glucagon-like Peptide-1 (GLP-1) Agonists Market

Ensuring equitable access and strengthening health systems will be essential to prevent widening health disparities.AgendaCo-chairsDr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMAModeratorDr Gaya Manori Gamhewage, Director, Department of Communication, WHOWelcomingDr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMAPresentation:WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adultsDr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr

As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do

Stop guessing and start maximizing your GLP-1 results with a complete, evidence-based system designed for long-term success

Your existing OSD line can't make it as-is

Discover what clinical research reveals about joint discomfort during Ozempic, Wegovy, or Rybelsus treatment, potential causes, and when to seek medical evaluation.

Ready to begin your GLP-1 weight loss journey